Actavis announced that the U.S. Food and Drug Administration (FDA) has approved a lower therapeutic dose of VIIBRYD (vilazodone HCl) (20mg) to accompany the 40 mg daily therapeutic dose. This supplemental new drug application (sNDA) approval for VIIBRYD expands dosing options available to health care providers when using VIIBRYD to treat their adult patients with MDD. The VIIBRYD 20mg therapeutic dose is now available in pharmacies.

VIIBRYD was approved in January 2011 as the first and only selective serotonin reuptake inhibitor (SSRI) and 5HT1a receptor partial agonist for the treatment of MDD in adults at a dose of 40 mg/day. The approval of the 20 mg dose fulfills a post-marketing commitment with the FDA to identify the minimum effective dose of vilazodone.